Lemonade Q3 Loss Widens, Revenue Increases; 2026 Revenue Guidance Lifted

MT newswire2026/11/05 13:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

09:03 AM EST, 11/05/2026 (MT Newswires) -- Lemonade (LMND) reported Q3 loss Thursday of $0.56 per diluted share, widening from a loss of $0.51 a year earlier. Four analysts polled by FactSet expected a loss of $0.61. Revenue for the quarter ended Sept. 30 was $336.1 million, up from $194.5 million a year earlier. Analysts expected $322.6 million. For Q4, the company expects revenue of $342 million to $346 million. Analysts expect $341.1 million. For 2026, the company raised its revenue guidance to between $1.23 billion and $1.24 billion, from prior outlook of $1.21 billion to $1.22 billion. Analysts expect $1.22 billion. Shares of the company were up 2.4% in premarket activity Thursday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12